ＣＤＫ阻害剤を含有する癌治療用医薬組成物

• Format: Patent
• Language: Japanese
• Published: 11.11.2021
• Subjects: HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; TESTING

ＣＤＫ阻害剤を含有する癌治療用医薬組成物を提供すること。ＣＤＫ阻害剤を含む、アンドロゲン除去療法に対して抵抗性を示す癌を治療するための医薬組成物。前記ＣＤＫ阻害剤が、アルボシジブ又はその製薬学的に許容される塩を含む。前記癌が、アンドロゲン受容体拮抗剤及び／又はアンドロゲン合成阻害剤に対して治療抵抗性を示す癌である。アンドロゲン受容体のリン酸化が亢進している被験者に投与される、アルボシジブ又はその製薬学的に許容される塩を有効成分として含む、癌治療用組成物。 Provided is a cancer treatment pharmaceutical composition that contains a CDK inhibitor. A pharmaceutical composition that includes a CDK inhibitor and is for treating cancers that demonstrate resistance to androgen removal therapy. The CDK inhibitor includes alvocidib or a pharmaceutically acceptable salt thereof. The cancers are cancers that demonstrate treatment resistance to androgen receptor antagonists and/or androgen synthesis inhibitors. A cancer treatment composition that includes alvocidib or a pharmaceutically acceptable salt thereof as an active ingredient and is to be administered to subjects that have enhanced androgen receptor phosphorylation.